Managed Access Programs (MAP)

A new Managed Access Program (MAP) for the treatment of sickle cell disease has been announced for Emmaus Life Sciences’ pharmaceutical grade L-glutamine treatment (PGLG). Read more


Leslie Morgan, CEO of Durbin talks about industry regulations, Managed Access Programmes and the future of pharma Read more


Robert Donnell, Durbin, specialist distributor of pharmaceuticals, medical and relief supplies, examines the increasing prevalence of managed access programmes and the challenges faced in getting the most appropriate drug to the patient in time Read more